Kymera Therapeutics (NASDAQ: KYMR) net income
Kymera Therapeutics reported a net loss of $311.4m for fiscal 2025; in fiscal 2024 it reported a net loss of $223.9m. Earnings per share were −$3.69.
Kymera Therapeutics's best year of the last 7 was fiscal 2019. It reported a loss in 7 of those 7 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$311.4m | — | −794.0% | −$3.69 |
| 2024 | −$223.9m | — | −475.6% | −$2.98 |
| 2023 | −$147.0m | — | −187.0% | −$2.52 |
| 2022 | −$154.8m | — | −330.6% | −$2.87 |
| 2021 | −$100.2m | — | −137.6% | −$2.09 |
| 2020 | −$45.6m | — | −134.0% | −$3.15 |
| 2019 | −$41.2m | — | −1,405.8% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Kymera Therapeutics net income compared with its sector
By net income for its latest fiscal year, Kymera Therapeutics ranks 450th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Kymera Therapeutics, −794.0%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 448th | Roivant Sciences | −$299.8m | −3,629.2% |
| 449th | Praxis Precision Medicines | −$303.3m | — |
| 450th | Kymera Therapeutics | −$311.4m | −794.0% |
| 451st | Ginkgo Bioworks | −$312.8m | −183.8% |
| 452nd | Replimune Group | −$313.9m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Kymera Therapeutics
- How much did Kymera Therapeutics earn in fiscal 2025?
- Kymera Therapeutics reported a net loss of $311.4m for fiscal 2025. In fiscal 2024 it reported a net loss of $223.9m.
- What are the earnings per share of Kymera Therapeutics?
- They were −$3.69 in fiscal 2025, compared with −$2.98 in fiscal 2024.
- Where does Kymera Therapeutics rank in its sector by net income?
- It ranks 450th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Kymera Therapeutics come from?
- From the annual report (Form 10-K) that Kymera Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Kymera Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Kymera Therapeutics: the Kymera Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.